Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Intellia Therapeutics, Inc.NASDAQ: NTLA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$94.03M, compared with -$111.83M a year earlier. Trailing-twelve-month EBITDA was -$384.61M.
Context
- EBITDA amounted to 586.3% of revenue in FY2025, down 292.7 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 13 analysts of -$342.69M (+13.6%) for the fiscal year ending Dec 2026, a slowdown from the +22.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$94.03M+1.4% QoQ
- Last fiscal yearDec 2025
- -$396.77M+22.0% YoY
- LTMMar 2026
- -$384.61M+25.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.9% | -11.3% | -27.2 pp |
| 1 year | +22.0% | +13.6% | -8.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (396.77M) USD
- Year-over-year change
- +22.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (396.77M) | +22.0% |
| FY2024 | 2024-12-31 | (508.74M) | -7.7% |
| FY2023 | 2023-12-31 | (472.22M) | -1.2% |
| FY2022 | 2022-12-31 | (466.61M) | -78.8% |
| FY2021 | 2021-12-31 | (261M) | — |
EBITDA vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 EBITDA of -$384.61M is the 9th highest of the 10 companies compared; the peer median is -$129.14M.
- Its year-over-year change of +25.4% is the 4th highest of 10, against a peer median of +21.0%.
- EBITDA amounts to 581.9% of revenue for NTLA, versus a peer median of 258.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | -$63.18M | +83.2% | — | 40.5% | |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$100.08M | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$129.14M | +6.4% | — | 713.8% | |
| LTM Jun 2026 | -$143.84M | -16.8% | — | 167.8% | |
| LTM Mar 2026 | -$187.06M | +2.3% | — | — | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$482.67M | -3.6% | — | 1917.5% | |
| Peer median (excluding NTLA) | -$129.14M | +21.0% | — | 258.7% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| Weighted Avg Shares | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Weighted Avg Shares (Diluted) | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.